💊 الأدوية من أ إلى ي 🧬 الأهداف 🛠 الأدوات 📚 الأدلة
جميع الأدوية تصنيفات الأدوية المجالات العلاجية الآثار الجانبية
الأدلة المسرد الجدول الزمني
المقارنات مسارات الأدوية عائلات الأدوية
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Uridine Triacetate

CHEMBL2107381 Phase 4 معتمد Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
370.3 g/mol
LogP
-0.5
Phase
4

Uridine triacetate is a prodrug that is cleaved in vivo to release uridine, which competitively inhibits the incorporation of fluorouracil (5-FU) metabolites into RNA and DNA, thereby rescuing normal cells from 5-FU toxicity. It is used as an antidote for 5-FU overdose or early-onset severe toxicity from 5-FU or capecitabine chemotherapy, and is also approved for hereditary orotic aciduria, a rare enzyme deficiency causing abnormal pyrimidine metabolism. Its mechanism of flooding the uridine pool reduces the relative incorporation of toxic 5-FU metabolites.

الوزن الجزيئي

370,3100 g/mol

LogP

-0,50

TPSA

138,00 Ų

قاعدة ليبينسكي للخمسة

ناجح

المجالات العلاجية

Pancreatic Cancer

آلية العمل

Counteracts the effects of a specific toxin or drug overdose through competitive antagonism, enhanced elimination, or direct chemical neutralization.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

الآلية

Counteracts the effects of a specific toxin or drug overdose through competitive antagonism, enhanced elimination, or direct chemical neutralization.

البنية ثنائية الأبعاد

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
CC(=O)OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@H](OC(C)=O)[C@@H]1OC(C)=O

                

                

                
                

                    
InChI

                    
InChI=1S/C15H18N2O9/c1-7(18)23-6-10-12(24-8(2)19)13(25-9(3)20)14(26-10)17-5-4-11(21)16-15(17)22/h4-5,10,12-14H,6H2,1-3H3,(H,16,21,22)/t10-,12-,13-,14-/m1/s1

                

                

                

                    
                    

                        
Molecular Formula

                        
C15H18N2O9

                    

                    
                    

                        
HBD / HBA

                        
1 / 9

                    

                    
                    

                        
الروابط القابلة للدوران

                        
8

                    

                    
                    
                    

                        
الذرات الثقيلة

                        
26

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
الأسئلة الشائعة

                

                    
                    

                        
                        

                            
Uridine triacetate is a prodrug that is cleaved in vivo to release uridine, which competitively inhibits the incorporation of fluorouracil (5-FU) metabolites into RNA and DNA, thereby rescuing normal cells from 5-FU toxicity. It is used as an antidote for 5-FU overdose or early-onset severe toxicity from 5-FU or capecitabine chemotherapy, and is also approved for hereditary orotic aciduria, a rare enzyme deficiency causing abnormal pyrimidine metabolism. Its mechanism of flooding the uridine pool reduces the relative incorporation of toxic …

                        

                    

                    

                    

                    
                    

                        
                        

                            
Counteracts the effects of a specific toxin or drug overdose through competitive antagonism, enhanced elimination, or direct chemical neutralization.

                        

                    

                    

                    

                    

                        
                        

                            
Yes, Uridine Triacetate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL2107381.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 20058.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.




        


        
        
    


    



    
إخلاء المسؤولية الطبية

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.